Bright Minds Biosciences (NASDAQ:DRUG) Earns Buy Rating from BTIG Research

Key Points

• BTIG Research reiterated a Buy rating on Bright Minds with a $147 target, implying about a 109.7% upside, and the analyst consensus is skewed positive (five Buys, one Hold) with an average target of $124.50.
• The stock opened at $70.10 (market cap ~$682M), trades with a negative PE, and has a one‑year range of $23.17–$123.75, with 50‑ and 200‑day moving averages around $79 and $71 respectively.
• Bright Minds is a clinical‑stage biotech developing small‑molecule, serotonin‑modulating neurotherapeutics — its lead candidate is BMB‑101, an oral 5‑HT2A modulator — and institutional investors now own about 40.52% of the shares after notable buys by firms like Ikarian and Millennium.

Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at BTIG Research in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $147.00 target price on the stock. BTIG Research's price target would indicate a potential upside of 109.70% from the stock's previous close.

Several other brokerages have also issued reports on DRUG. Zacks Research lowered shares of Bright Minds Biosciences from a "strong-buy" rating to a "hold" rating in a report on Tuesday, December 2nd. Wall Street Zen raised shares of Bright Minds Biosciences from a "sell" rating to a "hold" rating in a research note on Saturday, March 21st. HC Wainwright boosted their price target on shares of Bright Minds Biosciences from $115.00 to $145.00 and gave the company a "buy" rating in a research note on Wednesday, March 4th. Robert W. Baird set a $126.00 price objective on shares of Bright Minds Biosciences in a report on Friday, February 13th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Bright Minds Biosciences in a research report on Monday, December 1st. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $124.50.

Bright Minds Biosciences Stock Performance

DRUG opened at $70.10 on Monday. Bright Minds Biosciences has a one year low of $23.17 and a one year high of $123.75. The stock has a market capitalization of $682.07 million, a PE ratio of -36.32 and a beta of -6.03. The business's 50 day moving average price is $79.18 and its 200 day moving average price is $71.54.

Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) last posted its earnings results on Thursday, February 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.98) by $0.28. As a group, equities research analysts forecast that Bright Minds Biosciences will post -1.24 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bright Minds Biosciences

Several institutional investors have recently bought and sold shares of the company. Virtu Financial LLC purchased a new stake in Bright Minds Biosciences during the fourth quarter worth about $226,000. Invesco Ltd. purchased a new position in shares of Bright Minds Biosciences in the fourth quarter valued at approximately $328,000. Ikarian Capital LLC grew its holdings in shares of Bright Minds Biosciences by 933.1% in the fourth quarter. Ikarian Capital LLC now owns 159,421 shares of the company's stock valued at $12,441,000 after purchasing an additional 143,990 shares in the last quarter. Wellington Management Group LLP acquired a new position in shares of Bright Minds Biosciences in the fourth quarter valued at approximately $1,068,000. Finally, Millennium Management LLC increased its stake in Bright Minds Biosciences by 153.6% during the 4th quarter. Millennium Management LLC now owns 194,437 shares of the company's stock worth $15,174,000 after buying an additional 117,756 shares during the period. 40.52% of the stock is owned by institutional investors and hedge funds.

Bright Minds Biosciences Company Profile

Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.

The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.